Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Conivaptan: a step forward in the treatment of hyponatremia?

Hline SS, Pham PT, Pham PT, Aung MH, Pham PM, Pham PC.

Ther Clin Risk Manag. 2008 Apr;4(2):315-26.

2.

Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].

Ali F, Raufi MA, Washington B, Ghali JK.

Cardiovasc Drug Rev. 2007 Fall;25(3):261-79. Review. Erratum in: Cardiovasc Drug Rev. 2007 Winter;25(4):397.

PMID:
17919259
3.

Conivaptan: Evidence supporting its therapeutic use in hyponatremia.

Li-Ng M, Verbalis JG.

Core Evid. 2010 Jun 15;4:83-92.

5.

Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.

Serradeil-Le Gal C, Wagnon J, Valette G, Garcia G, Pascal M, Maffrand JP, Le Fur G.

Prog Brain Res. 2002;139:197-210. Review.

PMID:
12436936
6.

Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.

Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.

Prog Brain Res. 2008;170:473-512. doi: 10.1016/S0079-6123(08)00437-8. Review.

PMID:
18655903
7.

Hyponatremia: current treatment strategies and the role of vasopressin antagonists.

Cawley MJ.

Ann Pharmacother. 2007 May;41(5):840-50. Epub 2007 Apr 3. Review.

PMID:
17405824
8.

Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites.

Fernández-Varo G, Ros J, Cejudo-Martín P, Cano C, Arroyo V, Rivera F, Rodés J, Jiménez W.

J Hepatol. 2003 Jun;38(6):755-61.

PMID:
12763368
9.

The therapeutic use of vaptans for the treatment of dilutional hyponatremia.

Cassagnol M, Shogbon AO, Saad M.

J Pharm Pract. 2011 Aug;24(4):391-9. doi: 10.1177/0897190011415686. Epub 2011 Aug 3. Review.

PMID:
21813818
10.

AVP receptor antagonists as aquaretics: review and assessment of clinical data.

Verbalis JG.

Cleve Clin J Med. 2006 Sep;73 Suppl 3:S24-33. Review.

PMID:
16970150
11.

Current issues for nurse practitioners: Hyponatremia.

Haskal R.

J Am Acad Nurse Pract. 2007 Nov;19(11):563-79. Review.

PMID:
17970857
12.

Novel agents for the treatment of hyponatremia: a review of conivaptan and tolvaptan.

Ferguson-Myrthil N.

Cardiol Rev. 2010 Nov-Dec;18(6):313-21. doi: 10.1097/CRD.0b013e3181f5b3b7. Review.

PMID:
20926941
13.

Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.

Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N; Conivaptan Study Group..

Am J Nephrol. 2007;27(5):447-57. Epub 2007 Jul 26.

PMID:
17664863
14.

Recognition and treatment of hyponatremia in acutely ill hospitalized patients.

Patel GP, Balk RA.

Clin Ther. 2007 Feb;29(2):211-29. Review.

PMID:
17472815
15.

[Vasopressin receptor antagonists: the vaptans].

Villabona C.

Endocrinol Nutr. 2010 May;57 Suppl 2:41-52. doi: 10.1016/S1575-0922(10)70021-8. Review. Spanish.

PMID:
21130961
16.

Vasopressin dysregulation: hyponatremia, fluid retention and congestive heart failure.

LeJemtel TH, Serrano C.

Int J Cardiol. 2007 Aug 9;120(1):1-9. Epub 2007 Mar 8. Review.

PMID:
17346825
17.
18.

Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia.

Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, Smith N.

J Clin Endocrinol Metab. 2006 Jun;91(6):2145-52. Epub 2006 Mar 7.

PMID:
16522696
19.

Vasopressin excess and hyponatremia.

Pham PC, Pham PM, Pham PT.

Am J Kidney Dis. 2006 May;47(5):727-37. Review.

PMID:
16632011
20.

Intravenous conivaptan.

Moen MD, Keating GM.

Am J Cardiovasc Drugs. 2008;8(5):341-8; discussion 349.

PMID:
18828645

Supplemental Content

Support Center